摘要
目的评价调强放疗联合多西他赛单药同期化疗治疗老年局部晚期非小细胞肺癌的临床疗效。方法将79例初治老年局部晚期非小细胞肺癌患者随机分为试验组(40名)与对照组(39名),试验组患者采用调强放疗治疗并每3周使用多西他赛70 mg·m-2同期化疗2个周期;对照组仅采用调强放疗治疗;两组患者放疗结束后行多西他赛单药辅助化疗2周期,比较两组患者的近期、远期疗效和毒副反应。结果试验组治疗有效率为77.5%,显著高于对照组的61.5%(P=0.036);试验组2年局控率为22.5%、生存率为52.5%,均明显高于对照组的12.8%和35.9%(P=0.029,0.013);试验组放射性肺炎和骨髓抑制反应的发生率高于对照组(P=0.023,0.016),但不影响治疗。结论调强放疗联合多西他赛单药同期化疗治疗老年非小细胞肺癌的疗效较单纯调强放疗更好,安全性可以接受,值得推广应用。
Objective To evaluate the clinical efficacy of intensity modulation radiotherapy（IMRT） combined with docetaxel concurrent chemotherapy in the treatment of local advanced non-small cell lung cancer（LA-NSCLC） in elderly patients.MethodsIn this study,79 elderly patients who were firstly diagnosed with LA-NSCLC were randomly divided into experimental group（40 cases） and control group（39 cases）.The experimental group was treated by IMRT combined with concurrent docetaxel chemotherapy（70 mg·m^-2,every three weeks） for two cycles,while the control group was only treated by IMRT.By the end of IMRT treatment,all patients were treated with two more cycles of docetaxel monotherapy.After treatment,the clinical efficiency,2-year survival rate and toxic reactions were observed and compared.Results The response rate of the experimental group was significantly higher than that of control group（77.5% vs.61.5%,P=0.036）.The 2-year survival rate and disease control rate of the treatment group were significantly higher than those of control group,which were 22.5% vs.12.8%,P=0.029;and 52.5% vs.35.9%,P=0.013.The incidence of radiation pneumonitis and the bone marrow suppression response rate in the treatment group were higher than in the control group,but did not affect the results.Conclusion The IMRT combined with docetaxel concurrent chemotherapy showed better clinical efficacy than IMRT alone in the treatment of elderly LA-NSCLC patients.Its safety is acceptable and it is worth of being widely applied.
出处
《肿瘤药学》
CAS
2014年第5期379-382,共4页
Anti-Tumor Pharmacy
